The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Ahmedin Jemal - One of the best experts on this subject based on the ideXlab platform.
-
colorectal Cancer Incidence patterns in the united states 1974 2013
Journal of the National Cancer Institute, 2017Co-Authors: Rebecca L Siegel, Philip S Rosenberg, Stacey A Fedewa, William F Anderson, Kimberly D Miller, Ahmedin JemalAbstract:Background: Colorectal Cancer (CRC) Incidence in the United States is declining rapidly overall but, curiously, is increasing among young adults. Age-specific and birth cohort patterns can provide etiologic clues, but have not been recently examined. Methods: CRC Incidence trends in Surveillance, Epidemiology, and End Results areas from 1974 to 2013 (n = 490 305) were analyzed by five-year age group and birth cohort using Incidence rate ratios (IRRs) and age-period-cohort modeling. Results: After decreasing in the previous decade, colon Cancer Incidence rates increased by 1.0% to 2.4% annually since the mid-1980s in adults age 20 to 39 years and by 0.5% to 1.3% since the mid-1990s in adults age 40 to 54 years; rectal Cancer Incidence rates have been increasing longer and faster (eg, 3.2% annually from 1974–2013 in adults age 20–29 years). In adults age 55 years and older, Incidence rates generally declined since the mid-1980s for colon Cancer and since 1974 for rectal Cancer. From 1989–1990 to 2012–2013, rectal Cancer Incidence rates in adults age 50 to 54 years went from half those in adults age 55 to 59 to equivalent (24.7 vs 24.5 per 100 000 persons: IRR = 1.01, 95% confidence interval [CI] = 0.92 to 1.10), and the proportion of rectal Cancer diagnosed in adults younger than age 55 years doubled from 14.6% (95% CI = 14.0% to 15.2%) to 29.2% (95% CI = 28.5% to 29.9%). Age-specific relative risk by birth cohort declined from circa 1890 until 1950, but continuously increased through 1990. Consequently, compared with adults born circa 1950, those born circa 1990 have double the risk of colon Cancer (IRR = 2.40, 95% CI = 1.11 to 5.19) and quadruple the risk of rectal Cancer (IRR = 4.32, 95% CI = 2.19 to 8.51). Conclusions: Age-specific CRC risk has escalated back to the level of those born circa 1890 for contemporary birth cohorts, underscoring the need for increased awareness among clinicians and the general public, as well as etiologic research to elucidate causes for the trend. Further, as nearly one-third of rectal Cancer patients are younger than age 55 years, screening initiation before age 50 years should be considered.
-
bladder Cancer Incidence and mortality a global overview and recent trends
European Urology, 2017Co-Authors: Sebastien Antoni, Ahmedin Jemal, Ariana Znaor, Jacques Ferlay, Isabelle Soerjomataram, Freddie BrayAbstract:Abstract Context Bladder Cancer has become a common Cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder Cancer Incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder Cancer. Evidence acquisition Global bladder Cancer Incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder Cancer ranks as the ninth most frequently-diagnosed Cancer worldwide, with the highest Incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging Incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder Cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder Cancer Incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder Cancer statistics geographically or over time. Patient summary The main risk factor for bladder Cancer is tobacco smoking. The observed patterns and trends of bladder Cancer Incidence worldwide appear to reflect the prevalence of tobacco smoking.
-
international trends in anal Cancer Incidence rates
International Journal of Epidemiology, 2016Co-Authors: Farhad Islami, Joannie Lortettieulent, Freddie Bray, Jacques Ferlay, Ahmedin JemalAbstract:Background Previous studies have reported rapid increases in anal Cancer Incidence rates in seven high-income countries in North America, Europe and Oceania. There is very limited information on whether this pattern is replicated in other parts of the world. In this study, we examine recent trends in anal Cancer Incidence in 18 countries worldwide. Methods We calculated age-standardized Incidence rates for anal squamous cell carcinoma (ASCC) and anal adenocarcinoma (AAC) for a minimum of 13 years through to 2007, using data from the International Agency for Research on Cancer's Cancer Incidence in Five Continents series, and applied joinpoint regression models to assess changes in Incidence rates. We also conducted an extended analysis of the data from the USA through to 2012. Results ASCC was the main histological subtype in most of the countries considered in this analysis. The Incidence of ASCC increased in both men and women in several high-income countries, including Australia, Canada, Denmark, France, Italy, Netherlands, the UK and the USA, whereas it increased only in women in Colombia, Estonia, the Russian Federation, Slovakia and Switzerland. Conversely, there was little change in the Incidence of ASCC in either men or women in India, Israel, Japan, Singapore and Spain. The Incidence rates of AAC decreased or were stable in most populations. Conclusions The ASCC Incidence rates increased in both men and women or in women in all countries included in this study, except Asian countries and Spain, where the rates remained unchanged. Population-based preventive measures, including human papillomavirus vaccination and advocacy for safe sexual behaviours, may contribute to curbing the surging burden of the disease.
-
global Cancer Incidence and mortality rates and trends an update
Cancer Epidemiology Biomarkers & Prevention, 2016Co-Authors: Lindsey A Torre, Rebecca L Siegel, Elizabeth Ward, Ahmedin JemalAbstract:There are limited published data on recent Cancer Incidence and mortality trends worldwide. We used the International Agency for Research on Cancer's CancerMondial clearinghouse to present age-standardized Cancer Incidence and death rates for 2003-2007. We also present trends in Incidence through 2007 and mortality through 2012 for select countries from five continents. High-income countries (HIC) continue to have the highest Incidence rates for all sites, as well as for lung, colorectal, breast, and prostate Cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates. Mortality rates from these Cancers are declining in many HICs while they are increasing in LMICs. LMICs have the highest rates of stomach, liver, esophageal, and cervical Cancer. Although rates remain high in HICs, they are plateauing or decreasing for the most common Cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only). In contrast, rates in several LMICs are increasing for these Cancers due to increases in smoking, excess body weight, and physical inactivity. LMICs also have a disproportionate burden of infection-related Cancers. Applied Cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.
-
prostate Cancer Incidence and psa testing patterns in relation to uspstf screening recommendations
JAMA, 2015Co-Authors: Ahmedin Jemal, Rebecca L Siegel, Stacey A Fedewa, Chun Chieh Lin, Otis W Brawley, Elizabeth WardAbstract:Importance Prostate Cancer Incidence in men 75 years and older substantially decreased following the 2008 US Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)–based screening for this age group. It is unknown whether Incidence has changed since the USPSTF recommendation against screening for all men in May 2012. Objective To examine recent changes in stage-specific prostate Cancer Incidence and PSA screening rates following the 2008 and 2012 USPSTF recommendations. Design and Settings Ecologic study of age-standardized prostate Cancer Incidence (newly diagnosed cases/100 000 men aged ≥50 years) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries and PSA screening rate in the past year among men 50 years and older without a history of prostate Cancer who responded to the 2005 (n = 4580), 2008 (n = 3476), 2010 (n = 4157), and 2013 (n = 6172) National Health Interview Survey (NHIS). Exposures The USPSTF recommendations to omit PSA-based screening for average-risk men. Main Outcomes and Measures Prostate Cancer Incidence and Incidence ratios (IRs) comparing consecutive years from 2005 through 2012 by age (≥50, 50-74, and ≥75 years) and SEER summary stage categorized as local/regional or distant and PSA screening rate and rate ratios (SRRs) comparing successive survey years by age. Results Prostate Cancer Incidence per 100 000 in men 50 years and older (N = 446 009 in SEER areas) was 534.9 in 2005, 540.8 in 2008, 505.0 in 2010, and 416.2 in 2012; rates began decreasing in 2008 and the largest decrease occurred between 2011 and 2012, from 498.3 (99% CI, 492.8-503.9) to 416.2 (99% CI, 411.2-421.2). The number of men 50 years and older diagnosed with prostate Cancer nationwide declined by 33 519, from 213 562 men in 2011 to 180 043 men in 2012. Declines in Incidence since 2008 were confined to local/regional-stage disease and were similar across age and race/ethnicity groups. The percentage of men 50 years and older reporting PSA screening in the past 12 months was 36.9% in 2005, 40.6% in 2008, 37.8% in 2010, and 30.8% in 2013. In relative terms, screening rates increased by 10% (SRR, 1.10; 99% CI, 1.01-1.21) between 2005 and 2008 and then decreased by 18% (SRR, 0.82; 99% CI, 0.75-0.89) between 2010 and 2013. Similar screening patterns were found in age subgroups 50 to 74 years and 75 years and older. Conclusions and Relevance Both the Incidence of early-stage prostate Cancer and rates of PSA screening have declined and coincide with 2012 USPSTF recommendation to omit PSA screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality.
Freddie Bray - One of the best experts on this subject based on the ideXlab platform.
-
Testicular Cancer Incidence predictions in Europe 2010-2035: A rising burden despite population ageing.
International Journal of Cancer, 2019Co-Authors: Ariana Znaor, Niels E Skakkebaek, Katherine A Mcglynn, Ewa Rajpert-de Meyts, Mathieu Laversanne, T. Kulis, Jason Gurney, Diana Sarfati, Freddie BrayAbstract:Testicular Cancer is the most common Cancer among young men of European ancestry, with about one-third of all cases occurring in Europe. With the historically increasing trends in some high-Incidence populations reported to have stabilised in recent years, we aimed to assess recent trends and predict the future testicular Cancer Incidence burden across Europe. We extracted testicular Cancer (ICD-10 C62) Incidence data from Cancer Incidence in Five Continents Volumes VII-XI and complemented this with data published by registries from 28 European countries. We predicted Cancer Incidence rates and the number of incident cases in Europe in the year 2035 using the NORDPRED age-period-cohort model. Testicular Cancer Incidence rates will increase in 21 out of 28 countries over the period 2010-2035, with trends attenuating in the high-Incidence populations of Denmark, Norway, Switzerland and Austria. Although population ageing would be expected to reduce the number of cases, this demographic effect is outweighed by increasing risk, leading to an overall increase in the number of cases by 2035 in Europe, and by region (21, 13 and 32% in Northern, Western and Eastern Europe, respectively). Declines are however predicted in Italy and Spain, amounting to 12% less cases in 2035 in Southern Europe overall. In conclusion, the burden of testicular Cancer Incidence in Europe will continue to increase, particularly in historically lower-risk countries. The largest increase in the number of testicular Cancer patients is predicted in Eastern Europe, where survival is lower, reinforcing the need to ensure the provision of effective treatment across Europe.
-
Global Cancer Incidence in older adults, 2012 and 2035: A population-based study.
International Journal of Cancer, 2018Co-Authors: Sophie Pilleron, Diana Sarfati, Freddie Bray, Jacques Ferlay, Maryska L.g. Janssen-heijnen, Jérôme Vignat, Isabelle SoerjomataramAbstract:Population ageing has substantially contributed to the rising number of new Cancer cases worldwide. We document Cancer Incidence patterns in 2012 among older adults globally, and examine the changing magnitude of Cancer in this age group over the next decades. Using GLOBOCAN 2012 data, we presented the number and proportion of new Cancer cases, and the truncated age-standardised Incidence rates among adults aged 65 years and older for all Cancer sites combined and for the five most common Cancer sites by world region. We calculated the Incidence in 2035 by applying population projections, assuming no changes in rates. In 2012, 6.7 million new Cancer cases (47.5% of all Cancers) were diagnosed among older adults worldwide, with marked regional disparities. Nearly 48% of these cases occurred in less developed regions. Lung, colorectal, prostate, stomach and breast Cancers represented 55% of the global Incidence, yet distinct regional patterns were observed. We predict 14 million new Cancer cases by 2035, representing almost 60% of the global Cancer Incidence. The largest relative increase in Incidence is predicted in the Middle East and Northern Africa (+157%), and in China (+155%). Less developed regions will see an increase of new cases by 144%, compared to 54% in more developed regions. The expected increase in Cancer Incidence at older ages will have substantial economic and social impacts globally, posing considerable and unique challenge to healthcare systems in every world region, especially in those with limited resources and weaker health systems.
-
bladder Cancer Incidence and mortality a global overview and recent trends
European Urology, 2017Co-Authors: Sebastien Antoni, Ahmedin Jemal, Ariana Znaor, Jacques Ferlay, Isabelle Soerjomataram, Freddie BrayAbstract:Abstract Context Bladder Cancer has become a common Cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder Cancer Incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder Cancer. Evidence acquisition Global bladder Cancer Incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder Cancer ranks as the ninth most frequently-diagnosed Cancer worldwide, with the highest Incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging Incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder Cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder Cancer Incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder Cancer statistics geographically or over time. Patient summary The main risk factor for bladder Cancer is tobacco smoking. The observed patterns and trends of bladder Cancer Incidence worldwide appear to reflect the prevalence of tobacco smoking.
-
international trends in anal Cancer Incidence rates
International Journal of Epidemiology, 2016Co-Authors: Farhad Islami, Joannie Lortettieulent, Freddie Bray, Jacques Ferlay, Ahmedin JemalAbstract:Background Previous studies have reported rapid increases in anal Cancer Incidence rates in seven high-income countries in North America, Europe and Oceania. There is very limited information on whether this pattern is replicated in other parts of the world. In this study, we examine recent trends in anal Cancer Incidence in 18 countries worldwide. Methods We calculated age-standardized Incidence rates for anal squamous cell carcinoma (ASCC) and anal adenocarcinoma (AAC) for a minimum of 13 years through to 2007, using data from the International Agency for Research on Cancer's Cancer Incidence in Five Continents series, and applied joinpoint regression models to assess changes in Incidence rates. We also conducted an extended analysis of the data from the USA through to 2012. Results ASCC was the main histological subtype in most of the countries considered in this analysis. The Incidence of ASCC increased in both men and women in several high-income countries, including Australia, Canada, Denmark, France, Italy, Netherlands, the UK and the USA, whereas it increased only in women in Colombia, Estonia, the Russian Federation, Slovakia and Switzerland. Conversely, there was little change in the Incidence of ASCC in either men or women in India, Israel, Japan, Singapore and Spain. The Incidence rates of AAC decreased or were stable in most populations. Conclusions The ASCC Incidence rates increased in both men and women or in women in all countries included in this study, except Asian countries and Spain, where the rates remained unchanged. Population-based preventive measures, including human papillomavirus vaccination and advocacy for safe sexual behaviours, may contribute to curbing the surging burden of the disease.
-
international testicular Cancer Incidence trends generational transitions in 38 countries 1900 1990
Cancer Causes & Control, 2015Co-Authors: Ariana Znaor, Ahmedin Jemal, Mathieu Laversanne, Joannie Lortettieulent, Freddie BrayAbstract:Purpose Rapid increases in testicular Cancer Incidence have marked the second half of the last century. While these secular rises, observed mainly in countries attaining the highest levels of human development, appear to have attenuated in the last decade, rates continue to increase in countries transiting toward high developmental levels. The purpose of our study was to provide a comprehensive analysis and presentation of the cohort-specific trends in testicular Cancer Incidence rates in 38 countries worldwide.
Jacques Ferlay - One of the best experts on this subject based on the ideXlab platform.
-
Global Cancer Incidence in older adults, 2012 and 2035: A population-based study.
International Journal of Cancer, 2018Co-Authors: Sophie Pilleron, Diana Sarfati, Freddie Bray, Jacques Ferlay, Maryska L.g. Janssen-heijnen, Jérôme Vignat, Isabelle SoerjomataramAbstract:Population ageing has substantially contributed to the rising number of new Cancer cases worldwide. We document Cancer Incidence patterns in 2012 among older adults globally, and examine the changing magnitude of Cancer in this age group over the next decades. Using GLOBOCAN 2012 data, we presented the number and proportion of new Cancer cases, and the truncated age-standardised Incidence rates among adults aged 65 years and older for all Cancer sites combined and for the five most common Cancer sites by world region. We calculated the Incidence in 2035 by applying population projections, assuming no changes in rates. In 2012, 6.7 million new Cancer cases (47.5% of all Cancers) were diagnosed among older adults worldwide, with marked regional disparities. Nearly 48% of these cases occurred in less developed regions. Lung, colorectal, prostate, stomach and breast Cancers represented 55% of the global Incidence, yet distinct regional patterns were observed. We predict 14 million new Cancer cases by 2035, representing almost 60% of the global Cancer Incidence. The largest relative increase in Incidence is predicted in the Middle East and Northern Africa (+157%), and in China (+155%). Less developed regions will see an increase of new cases by 144%, compared to 54% in more developed regions. The expected increase in Cancer Incidence at older ages will have substantial economic and social impacts globally, posing considerable and unique challenge to healthcare systems in every world region, especially in those with limited resources and weaker health systems.
-
bladder Cancer Incidence and mortality a global overview and recent trends
European Urology, 2017Co-Authors: Sebastien Antoni, Ahmedin Jemal, Ariana Znaor, Jacques Ferlay, Isabelle Soerjomataram, Freddie BrayAbstract:Abstract Context Bladder Cancer has become a common Cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder Cancer Incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder Cancer. Evidence acquisition Global bladder Cancer Incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder Cancer ranks as the ninth most frequently-diagnosed Cancer worldwide, with the highest Incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging Incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder Cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder Cancer Incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder Cancer statistics geographically or over time. Patient summary The main risk factor for bladder Cancer is tobacco smoking. The observed patterns and trends of bladder Cancer Incidence worldwide appear to reflect the prevalence of tobacco smoking.
-
international trends in anal Cancer Incidence rates
International Journal of Epidemiology, 2016Co-Authors: Farhad Islami, Joannie Lortettieulent, Freddie Bray, Jacques Ferlay, Ahmedin JemalAbstract:Background Previous studies have reported rapid increases in anal Cancer Incidence rates in seven high-income countries in North America, Europe and Oceania. There is very limited information on whether this pattern is replicated in other parts of the world. In this study, we examine recent trends in anal Cancer Incidence in 18 countries worldwide. Methods We calculated age-standardized Incidence rates for anal squamous cell carcinoma (ASCC) and anal adenocarcinoma (AAC) for a minimum of 13 years through to 2007, using data from the International Agency for Research on Cancer's Cancer Incidence in Five Continents series, and applied joinpoint regression models to assess changes in Incidence rates. We also conducted an extended analysis of the data from the USA through to 2012. Results ASCC was the main histological subtype in most of the countries considered in this analysis. The Incidence of ASCC increased in both men and women in several high-income countries, including Australia, Canada, Denmark, France, Italy, Netherlands, the UK and the USA, whereas it increased only in women in Colombia, Estonia, the Russian Federation, Slovakia and Switzerland. Conversely, there was little change in the Incidence of ASCC in either men or women in India, Israel, Japan, Singapore and Spain. The Incidence rates of AAC decreased or were stable in most populations. Conclusions The ASCC Incidence rates increased in both men and women or in women in all countries included in this study, except Asian countries and Spain, where the rates remained unchanged. Population-based preventive measures, including human papillomavirus vaccination and advocacy for safe sexual behaviours, may contribute to curbing the surging burden of the disease.
-
an international comparison of male and female breast Cancer Incidence rates
International Journal of Cancer, 2013Co-Authors: Diana Ly, David Forman, Jacques Ferlay, Louise A Brinton, Michael B CookAbstract:Global international trends in female breast Cancer Incidence have been described previously but no comparable analysis of male breast Cancer Incidence rates has been conducted. We obtained male and female case and population data using Cancer Incidence in Five Continents (CI5). We calculated age-adjusted, sex-specific Incidence rates and female-to-male Incidence rate ratios (FMIRRs) and compared trends of such for the period 1988–2002. This analysis included 8,681 male breast Cancer cases and 1.14 million female breast Cancer cases. The highest male Incidence rate was observed in Israel at 1.24 per 100,000 man-years, and the highest female Incidence rate was observed in the United States at 90.7 per 100,000 woman-years. The lowest Incidence rates for males (0.16) and females (18.0) were observed in Thailand. In general, male breast Cancer Incidence trends were variable; a minority of countries displayed evidence for an increase. In contrast, female Incidence rates have been increasing in a majority of countries. The Pearson correlation coefficient (r) for male and female breast Cancer Incidence rates by country during 1988–2002 was 0.69. Male breast Cancer rates were generally less than 1 per 100,000 man-years, in contrast to the much higher rates of female breast Cancer, providing for an overall FMIRR of 122. The differences in both Incidence rates and time trends between males and females may reflect sex differences in underlying risk factors, pathogenesis, and/or overdiagnosis. Conversely, the high correlation between male and female breast Cancer Incidences may indicate that both sexes share some common risk factors for breast Cancer.
-
fifty years of Cancer Incidence ci5 i ix
International Journal of Cancer, 2010Co-Authors: Max D Parkin, Freddie Bray, Jacques Ferlay, Maria Paula Curado, Brenda K Edwards, Hai Rim Shin, David FormanAbstract:The Cancer Incidence in Five Continents (CI5) series comprises nine volumes that bring together peer-reviewed results from population-based Cancer registries worldwide. The aim of each is to make available comparable data on Cancer Incidence from as wide a range of geographical locations as possible. In addition, the existence of long time series of data allows the evolution of risk in different populations over time to be studied. The CI5 I-IX database brings together the results from all nine volumes, spanning a period of some 50 years. In addition, unpublished annual data, with more diagnostic detail, are made available for many Cancer registries with 15 or more years of recent data. We describe the construction and composition of the CI5 databases, and provide examples of how they can be used to prepare tables and graphs comparing Incidence rates between populations. This is the classical role of descriptive statistics: to allow formulation of hypotheses that might explain the observed differences (geographically, over time, in population subgroups) and that can be tested by further study. Such statistics are also essential components in the planning and evaluation of Cancer control programmes.
Hiroshi Nishimoto - One of the best experts on this subject based on the ideXlab platform.
-
Cancer Incidence and Incidence rates in japan in 2009 a study of 32 population based Cancer registries for the monitoring of Cancer Incidence in japan mcij project
Japanese Journal of Clinical Oncology, 2015Co-Authors: Megumi Hori, Tomohiro Matsuda, Akiko Shibata, Kota Katanoda, Tomotaka Sobue, Hiroshi NishimotoAbstract:The Japan Cancer Surveillance Research Group aimed to estimate the Cancer Incidence in Japan in 2009 based on data collected from 32 of 37 population-based Cancer registries, as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project. The Incidence of only primary invasive Cancer in Japan for 2009 was estimated to be 775 601. Stomach Cancer and breast Cancer were the leading types of Cancer in males and females, respectively.
-
an updated report of the trends in Cancer Incidence and mortality in japan
Japanese Journal of Clinical Oncology, 2013Co-Authors: Kota Katanoda, Tomohiro Matsuda, Akiko Shibata, Tomotaka Sobue, Ayako Matsuda, Yoshikazu Nishino, Manabu Fujita, Midori Soda, Akiko Ioka, Hiroshi NishimotoAbstract:Objective: The analysis of Cancer trends in Japan has only been sporadically reported. We present a comprehensive report on the trends in Cancer Incidence and mortality in Japan using the most recent population-based data. Methods: National Cancer mortality data between 1958 and 2011 were obtained from published vital statistics. Cancer Incidence data between 1985 and 2007 were obtained from high-quality population-based Cancer registries of four prefectures (Miyagi, Yamagata, Fukui and Nagasaki). Joinpoint regression analysis was performed to examine the trends in agestandardized rates of Cancer Incidence and mortality. Results: All-Cancer mortality decreased from the mid-1990s, with an annual percent change of 21.3% (95% confidence interval: 21.4, 21.3), while all-Cancer Incidence continually increased from 1985, with an annual percent change of 0.7% (95% confidence interval: 0.6, 0.8). Major Cancer sites, particularly the liver, colorectum and lung (males), showed a pattern of increasing Incidence and mortality rates until the mid-1990s, stabilizing or decreasing thereafter. Stomach Cancer showed a long-term decreasing trend for both Incidence and mortality, while female breast Cancer showed a continuously increasing trend. The Incidence of prostate Cancer, particularly at the localized stage, increased rapidly between 2000 and 2003, while that of mortality decreased from 2004. No changes were detected in the Incidence or mortality for colorectal, female breast or cervical Cancers after the establishment of national screening programs for these Cancers. Conclusions: The analysis of Cancer trends in Japan revealed a recent decrease in mortality and a continuous increase in Incidence, which are considered to reflect changes in the underlying risk factors such as tobacco smoking and infection, and are partially explained by early detection and improved treatment.
-
Cancer Incidence and Incidence rates in japan in 2007 a study of 21 population based Cancer registries for the monitoring of Cancer Incidence in japan mcij project
Japanese Journal of Clinical Oncology, 2013Co-Authors: Ayako Matsuda, Tomohiro Matsuda, Akiko Shibata, Kota Katanoda, Tomotaka Sobue, Hiroshi NishimotoAbstract:The Japan Cancer Surveillance Research Group aimed to estimate the Cancer Incidence in Japan in 2007 based on data collected from 21 out of 33 population-based Cancer registries as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project. The total number of Incidences in Japan for 2007 was estimated to be 704 090 (C00–C96). Stomach Cancer and breast Cancer were the leading types of Cancer in males and females, respectively.
-
Cancer Incidence and Incidence rates in japan in 2006 based on data from 15 population based Cancer registries in the monitoring of Cancer Incidence in japan mcij project
Japanese Journal of Clinical Oncology, 2012Co-Authors: Ayako Matsuda, Tomohiro Matsuda, Akiko Shibata, Kota Katanoda, Tomotaka Sobue, Hiroshi NishimotoAbstract:The Japan Cancer Surveillance Research Group estimated the Cancer Incidence in 2006 as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project, on the basis of data collected from 15 of 32 population-based Cancer registries. The total number of Incidences in Japan for 2006 was estimated as 664 398 (C00–C96). The leading Cancer site was stomach for men and breast for women. Age-standardized Incidence rates remained at almost the same level as for the previous 3 years.
-
Cancer Incidence and Incidence rates in japan in 2008 a study of 25 population based Cancer registries for the monitoring of Cancer Incidence in japan mcij project
Japanese Journal of Clinical Oncology, 2012Co-Authors: Ayako Matsuda, Tomohiro Matsuda, Akiko Shibata, Kota Katanoda, Tomotaka Sobue, Hiroshi NishimotoAbstract:The Japan Cancer Surveillance Research Group estimated the Cancer Incidence in 2006 as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project, on the basis of data collected from 15 of 32 population-based Cancer registries. The total number of Incidences in Japan for 2006 was estimated as 664 398 (C00–C96). The leading Cancer site was stomach for men and breast for women. Age-standardized Incidence rates remained at almost the same level as for the previous 3 years.
Michael C R Alavanja - One of the best experts on this subject based on the ideXlab platform.
-
Cancer Incidence among pesticide applicators exposed to dicamba in the agricultural health study
Environmental Health Perspectives, 2006Co-Authors: Claudine Samanic, Jennifer A Rusiecki, Mustafa Dosemeci, Lifang Hou, Jane A Hoppin, Dale P Sandler, Jay H Lubin, Aaron Blair, Michael C R AlavanjaAbstract:BackgroundDicamba is an herbicide commonly applied to crops in the United States and abroad. We evaluated Cancer Incidence among pesticide applicators exposed to dicamba in the Agricultural Health ...
-
Cancer Incidence among pesticide applicators exposed to atrazine in the agricultural health study
Journal of the National Cancer Institute, 2004Co-Authors: Jennifer A Rusiecki, Mustafa Dosemeci, Jane A Hoppin, Jay H Lubin, Aaron Blair, Anneclaire J De Roos, Michael C R AlavanjaAbstract:Background: Atrazine is the most heavily applied agricultural pesticide for crop production in the United States. Both animal and human studies have suggested that atrazine is possibly carcinogenic, but results have been mixed. We evaluated Cancer Incidence in atrazine-exposed pesticide applicators among 53 943 participants in the Agricultural Health Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. Methods: We obtained detailed pesticide exposure information using a selfadministered questionnaire completed at the time of enrollment (1993‐1997). Cancer Incidence was followed through December 31, 2001. We used adjusted Poisson regression to calculate rate ratios (RRs) and 95% confidence intervals (CIs) of multiple types of Cancer among atrazine exposed applicators. P trend values were calculated using atrazine exposure as a continuous variable, and all statistical tests were two-sided. Two exposure metrics were used: quartiles of lifetime days of exposure and quartiles of intensity-weighted lifetime days of exposure. Results: 36 513 (68%) applicators reported ever using atrazine; exposure was not associated with overall Cancer Incidence. Comparisons of Cancer Incidence in applicators with the highest atrazine exposure and those with the lowest exposure, assessed by lifetime days (RR LD ) and intensity-weighted lifetime days (RR IWLD )o f exposure yielded the following results: prostate Cancer, RRLD 0.88, 95% CI 0.63 to 1.23, Ptrend .26, and RRIWLD 0.89, 95% CI 0.63 to 1.25, Ptrend .35; lung Cancer, RRLD 1.91, 95% CI 0.93 to 3.94, Ptrend .08, and RRIWLD 1.37, 95% CI 0.65 to 2.86, Ptrend .19; bladder Cancer, RRLD 3.06, 95% CI 0.86 to 10.81, Ptrend .18, and RRIWLD 0.85, 95% CI 0.24 to 2.94, Ptrend .71; non-Hodgkin lymphoma, RRLD 1.61, 95% CI 0.62 to 4.16, Ptrend .35, and RRIWLD 1.75, 95% CI 0.73 to 4.20, Ptrend .14; and multiple myeloma, RRLD 1.60, 95% CI 0.37 to 7.01, Ptrend .41, and RRIWLD 2.17, 95% CI 0.45 to 10.32, Ptrend .21. Conclusions: Our analyses did not find any clear associations between atrazine exposure and any Cancer analyzed. However, further studies are warranted for tumor types in which there was a suggestion of trend (lung, bladder, non-Hodgkin lymphoma, and multiple myeloma). [J Natl Cancer Inst 2004;96:1375‐82]
